Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nuvate AL Gel is a topical combination therapy developed by Galcare Pharmaceutical for the treatment of inflammatory and pruritic dermatological conditions. It contains clobetasol propionate, a potent synthetic corticosteroid, and ammonium lactate, a humectant. Clobetasol propionate acts as a glucocorticoid receptor agonist, suppressing the release of inflammatory mediators to reduce swelling, redness, and itching. Ammonium lactate serves as a moisturizing agent that helps retain skin moisture and promotes the exfoliation of dead skin cells, making the formulation particularly useful for conditions characterized by both inflammation and dryness. The product is marketed in India for various corticosteroid-responsive dermatoses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Nuvate AL Gel.